Related Experiment Video
Updated: Jun 5, 2026
04:51
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Stevens - johnson syndrome induced by sodium valproate
P N Suresh Kumar1, S Kishore Kumar
1Director, Institute of Mental Health & Neurosciences, Kozhikode-673016.
Indian Journal of Psychiatry
|January 13, 2011
Summary
Sodium valproate, used for manic episodes, can cause Stevens-Johnson syndrome (SJS), a severe skin reaction. Prompt treatment with steroids and supportive care led to recovery in this case.
Area of Science:
- Pharmacovigilance
- Dermatology
- Neuropsychiatry
Background:
- Stevens-Johnson syndrome (SJS) is a rare but serious adverse drug reaction.
- Sodium valproate is a commonly prescribed anticonvulsant and mood stabilizer.
Purpose of the Study:
- To report a case of SJS following sodium valproate treatment.
- To highlight the potential for severe cutaneous reactions to sodium valproate.
Main Methods:
- Case report of a 55-year-old male treated for a manic episode.
- Clinical observation of cutaneous manifestations consistent with SJS.
- Review of treatment protocols and patient outcomes.
Main Results:
- The patient developed SJS after two weeks of sodium valproate therapy.
- Treatment included systemic steroids, antihistamines, and topical calamine lotion.
- Complete recovery from SJS occurred within a few weeks.
Conclusions:
- Sodium valproate can precipitate Stevens-Johnson syndrome.
- Early recognition and management are crucial for favorable outcomes in SJS.
- This case underscores the importance of monitoring for adverse cutaneous reactions during valproate therapy.
Related Concept Videos
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...